EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy

Helmneh M Sineshaw iD, Christina M Zettler iD, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M Sarpong, Claire Bai, Andrew J Belli, Laura L Fernandes iD, Ching-Kun Wang

Cancer Medicine · 2024-04 · 13 (7)

DOI: 10.1002/cam4.7173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.04.2024. Verfasst von Helmneh M Sineshaw und 9 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although initial treatment of diffuse large B‐cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contemporary data on characteristics, treatment patterns, and outcomes for R/R‐DLBCL.

Methods

Patients with incident (January 2016 to March 2021) DLBCL age ≥18 years who initiated first‐line (1L) therapy were identified from the COTA real‐world database. Baseline characteristics, treatment patterns, and real‐world outcomes, including time to next treatment (rwTTNT) and overall survival (rwOS), were assessed for the study population and by line of therapy (LOT).

Results

A total of 1347 eligible DLBCL patients were identified. Of these, 340 (25.2%) proceeded to receive 2L, of whom 141 (41.5%) proceeded to receive 3L, of whom 51 (36.2%) proceeded to receive 4L+. Most common treatments were R‐CHOP in 1L (63.6%), stem cell transplant (SCT) in 2L (17.9%), polatuzumab vedotin, bendamustine, and rituximab (Pola‐BR) in 3L (9.9%), and chimeric antigen receptor T‐cell therapy (CAR‐T) in 4L (11.8%). Treatment patterns were more variable in later LOTs. One‐ and 3‐year rwOS from 1L initiation were 88.5% and 78.4%, respectively. Patients who received later LOTs experienced numerically lower 1‐ and 3‐year rwOS (from 2L initiation: 62.4% and 46.4%, respectively).

Conclusions

In this real‐world analysis, 25.2% of patients experienced R/R‐DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansAdolescentRituximabTreatment OutcomeCyclophosphamideVincristinePrednisoneDoxorubicinAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

DLBCLoutcomesrelapsed/refractorysurvivaltreatment

Substanzen

RituximabCyclophosphamideVincristinePrednisoneDoxorubicin

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • COTA, Inc., New York, New York, USA.

ORCID-Profile: Helmneh M Sineshaw, Christina M Zettler, Laura L Fernandes

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Sineshaw, H. M., Zettler, C. M., Prescott, J., Garg, M., Chakraborty, S., Sarpong, E. M., Bai, C., Belli, A. J., Fernandes, L. L., & Wang, C. K. (2024). Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy. Cancer Medicine, 13(7). https://doi.org/10.1002/cam4.7173

Vancouver

Sineshaw HM, Zettler CM, Prescott J, Garg M, Chakraborty S, Sarpong EM, et al. Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy. Cancer Medicine. 2024;13(7). doi:10.1002/cam4.7173

BibTeX
@article{Sineshaw2024,
  author = {Sineshaw, Helmneh M and Zettler, Christina M and Prescott, Jennifer and Garg, Mahek and Chakraborty, Samhita and Sarpong, Eric M and Bai, Claire and Belli, Andrew J and Fernandes, Laura L and Wang, Ching-Kun},
  title = {Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {7},
  doi = {10.1002/cam4.7173}
}
Kostenlos starten →